Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04165837 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects
A Phase 1 study, sponsored by 1ST Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT04165837 is a Phase 1 study that has completed, run by 1ST Biotherapeutics. The registered enrollment target is 24 participants.
The verdict
NCT04165837, a Phase 1 study, has completed, sponsored by 1ST Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of oral doses of FB-101 in healthy subjects.
Interventions
- DRUG Placebo
- DRUG FB-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-10-14 |
| Est. Completion | 2022-07-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04165837
The ClinicalTrials.gov registry entry for NCT04165837 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is 1ST Biotherapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04165837 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04165837 about?
NCT04165837 is a clinical study titled "Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects". The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of oral doses of FB-101 in healthy subjects.
What is the current status of trial NCT04165837?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2019-10-14. Estimated completion is 2022-07-14.
What interventions are being tested in trial NCT04165837?
The interventions under investigation include: Placebo (DRUG), FB-101 (DRUG).
Who is sponsoring clinical trial NCT04165837?
This trial is sponsored by 1ST Biotherapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.